Anthos Capital, an investment firm, and SALT Fund, an active fund manager, led a $100m series C funding round in Cambrian Biopharma, a private, clinical-stage biopharmaceutical company, with participation from Apeiron Investment Group, Future Ventures and Moore Capital. "We are thrilled to have such a visionary group of investors partnering with us to further Cambrian's mission. It's an honor to welcome Paul and Brent to the board to help Cambrian become the leader in the longevity biotech field. The capital from our Series C round equips us to continue advancing our existing pipeline and also partner with more scientific innovators to bring more programs under the Cambrian banner," James Peyer, Cambrian CEO and Co-Founder.